Inhalable Polymeric Nanoparticle Vaccine for Lysosome‐Targeting Co‐Delivery of Antigen and Adjuvant With Enhanced Immunoprotection
Advanced Materials · 2026
DOI: 10.1002/adma.73112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Chenxi Dai und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China. Hauptthemen laut MEDLINE: Lysosomes, Polymers, Adjuvants, Immunologic, Adjuvants, Vaccine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: National Key R&D Program of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Conventional subunit vaccines, typically formulated as a simple antigen and adjuvant mixture, suffer from premature clearance and poor synchronization of antigen and adjuvant, resulting in suboptimal immune activation. Here, we develop an amphipathic polymer, YAXA, featuring acid‐labile imine bonds for pH‐responsive degradation and terminal NHS‐activated esters for covalent conjugation of protective antigen. Through hydrophilic‐hydrophobic co‐assembly with the hydrophobic TLR7 agonist 3M‐052, followed by antigen conjugation, YAXA forms an inhalable nanoparticle vaccine, YM3.7, in which the antigen is displayed on the hydrophilic surface while the adjuvant is encapsulated in the hydrophobic core. Following aerosolized intratracheal inoculation into the lung, YM3.7 is efficiently internalized by antigen‐presenting cells and trafficked into the lysosome, where acidic conditions trigger its dissociation and co‐release of antigen and adjuvant. This lysosome‐targeted, spatiotemporally synchronized delivery couples antigen presentation with TLR7/NF‐κB activation, driving robust immune responses, including antigen‐presenting cell maturation, germinal center formation, systemic and lung‐resident B/T cell response, and IgG/sIgA production. In lethal pneumonia models induced by Pseudomonas aeruginosa or Staphylococcus aureus , YM3.7 markedly improves survival over a conventional antigen and adjuvant mixture. This research establishes a paradigm for developing next‐generation inhalable nanoparticle vaccines, capable of spatiotemporally coordinating innate immunity, humoral immunity, mucosal immunity, and cell‐mediated immunity to provide enhanced immunoprotection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.
- Beijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China.
ORCID-Profile: Hanchen Zhang, Haihua Xiao, Dongsheng Zhou
Förderung
- National Key R&D Program of China
- National Key Research and Development Program of China
Zitieren
APA
Dai, C., Zhang, H., Hu, L., Song, X., Zhang, X., Fu, S., Li, Z., Xiao, H., & Zhou, D. (2026). Inhalable Polymeric Nanoparticle Vaccine for Lysosome‐Targeting Co‐Delivery of Antigen and Adjuvant With Enhanced Immunoprotection. Advanced Materials. https://doi.org/10.1002/adma.73112
Vancouver
Dai C, Zhang H, Hu L, Song X, Zhang X, Fu S, et al. Inhalable Polymeric Nanoparticle Vaccine for Lysosome‐Targeting Co‐Delivery of Antigen and Adjuvant With Enhanced Immunoprotection. Advanced Materials. 2026. doi:10.1002/adma.73112
BibTeX
@article{Dai2026,
author = {Dai, Chenxi and Zhang, Hanchen and Hu, Lingfei and Song, Xiaolin and Zhang, Xi and Fu, Shengnan and Li, Zhixin and Xiao, Haihua and Zhou, Dongsheng},
title = {Inhalable Polymeric Nanoparticle Vaccine for Lysosome‐Targeting Co‐Delivery of Antigen and Adjuvant With Enhanced Immunoprotection},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.73112}
}
EUVIMED